Psychedelics like psilocybin, DMT, and LSD are increasingly
welcomed in behavioral and psychiatric research, with
implications that extend well beyond neuroscience. This
webinar will delve into efforts to transform anecdotal evidence
into supported medical interventions through systematic
research and controlled clinical trials.
  • Psychopharmacology: From Principle to Practice
  • An introduction to Drug Science’s Medical Psychedelics Working Group
  • 1596224028-5c3d5e59eda56a6e
    David Nutt, DM, FRCP, FRCPSYCH, FSB, FMEDSCI
    Professor, Neuropsychopharmacology Unit Centre for Psychiatry, Imperial College London
    David Nutt is currently the Edmond J. Safra Professor of Neuropsychopharmacology and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences. After 11+ entry to Bristol Grammar School, David was awarded an Open Scholarship to Downing College Cambridge and then completed his medical training at Guy's Hospital London, continuing in neurology to MRCP.

    After completing his psychiatric training in Oxford, he continued there as a lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then spent two years as Chief of the Section of Clinical Science in the National Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. On returning to England in 1988, he set up the Psychopharmacology Unit in Bristol University, an interdisciplinary research grouping spanning the departments of Psychiatry and Pharmacology, before moving to Imperial College London in December 2008 where he leads a similar group with a particular focus on brain imaging, especially PET.